QUESTIONS_AND_ANSWERS_Studies_to_Enhance_FDA_Communications_Medical_Countermeasures_2.doc

QUESTIONS AND ANSWERS #2

SOLICITATION NUMBER # FDA-16-RFP-1160119

Studies to Enhance FDA Communications Addressing Medical Countermeasures

Question 01 RFP p.1, Section 2.1: Will the contracting resulting from this RFP be firm fixed pricing?

Answer 01 Firm Fixed Pricing

Question 02 RFP, p.3, Section 3.2, 2nd paragraph: The SOW proposes 24 groups in 5 cities. Should this be 25 groups, allowing 5 focus groups in each city?

Answer 02 Yes. 25 groups, 5 focus groups in each city.

Question 03 RFP, p. 3, Section 3.2, 2nd paragraph: The SOW stipulates that focus groups will be video recorded. In past projects, IRB/OMB representatives have expressed concerns about videotaping because it violates respondent confidentiality. Is it appropriate to substitute video streaming (allowing FDA staff to watch the focus groups in real time) and eliminate video recording?

Answer 03 Yes to video streaming vs video capture if it violates OMB.

Question 04 Have you identified the 5 cities where your focus groups will be conducted?

Answer 04 Responders should recommend cities in their proposals.

Question 05 What is the anticipated contract type-firm fixed price (FFP), T&M, etc.

Answer 05 Firm Fixed Price (FFP).